orlotamab

Macrogenics takes another shot at a novel immune checkpoint
EP Vantage
Thu, 04/22/21 - 10:49 am
Macrogenics
MGC018
orlotamab
enoblituzumab
prostate cancer
metastatic castration-resistant prostate cancer